CervoMed Inc. Total Assets
CervoMed Inc. total assets. Based on the latest financial reports, CervoMed Inc. (CRVO) holds total assets worth $25.99 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CervoMed Inc. (CRVO) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of CervoMed Inc. (1998–2025)
Total assets of CervoMed Inc. from 1998 to 2025. This chart illustrates how CervoMed Inc.'s total assets have evolved over time, based on quarterly financial data. See CervoMed Inc. share price for real-time trading data and today's change.
CervoMed Inc. - Asset Composition Analysis
CervoMed Inc. Total Assets Breakdown (December 2025)
CervoMed Inc. total assets breakdown as of December 2025. CervoMed Inc.'s total assets of $25.99 Million consist of 96.4% current assets and 3.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 35.2% |
| Accounts Receivable | $426.99K | 1.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1998–2025)
This chart illustrates how CervoMed Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of CervoMed Inc. to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CervoMed Inc.'s current assets represent 96.4% of total assets in 2025, an increase from 93.0% in 1998.
- Cash Position: Cash and equivalents constituted 35.2% of total assets in 2025, up from 0.0% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1998.
- Asset Diversification: The largest asset category is accounts receivable at 1.8% of total assets.
CervoMed Inc. Competitors by Total Assets
Key competitors of CervoMed Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
CervoMed Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.57 | 20.63 | 14.81 |
| Quick Ratio | 8.57 | 20.63 | 14.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $22.96 Million | $36.24 Million | $37.97 Million |
CervoMed Inc. - Advanced Valuation Insights
This section examines the relationship between CervoMed Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.66 |
| Latest Market Cap to Assets Ratio | 1.00 |
| Asset Growth Rate (YoY) | -45.7% |
| Total Assets | $23.40 Million |
| Market Capitalization | $23.43 Million USD |
Valuation Analysis
Near Book Valuation: The market values CervoMed Inc.'s assets close to their book value (1.00x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: CervoMed Inc.'s assets decreased by 45.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for CervoMed Inc. (1998–2025)
The table below shows the annual total assets of CervoMed Inc. from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $23.40 Million | -45.69% |
| 2024-12-31 | $43.08 Million | +332.00% |
| 2023-12-31 | $9.97 Million | +139.86% |
| 2022-12-31 | $4.16 Million | -89.01% |
| 2021-12-31 | $37.84 Million | +36.46% |
| 2020-12-31 | $27.73 Million | +14.21% |
| 2019-12-31 | $24.28 Million | +33.38% |
| 2018-12-31 | $18.20 Million | -30.38% |
| 2017-12-31 | $26.15 Million | +49.54% |
| 2016-12-31 | $17.48 Million | +668.01% |
| 2015-12-31 | $2.28 Million | -94.68% |
| 2014-12-31 | $42.78 Million | +133.20% |
| 2013-12-31 | $18.34 Million | +649.87% |
| 2012-12-31 | $2.45 Million | -33.41% |
| 2011-12-31 | $3.67 Million | -34.11% |
| 2010-12-31 | $5.58 Million | +30.18% |
| 2009-12-31 | $4.28 Million | -20.13% |
| 2008-12-31 | $5.36 Million | -20.00% |
| 2007-12-31 | $6.70 Million | -69.78% |
| 1999-12-31 | $22.18 Million | +19.90% |
| 1998-12-31 | $18.50 Million | -- |
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and sl… Read more